Saved Activities


0 Activities
0 Activities

Current and Emerging JAK Inhibitors


Activity Info

A variety of agents are in late-stage trials for the management of myelofibrosis (MF), targeting different cellular processes. This module explains the mechanism of action and clinical results of current and emerging therapies. Strategies to prevent, monitor, and manage treatment related adverse effects are also discussed. Learn to apply shared-decision making to develop individualized, patient-centric treatment plans considering healthcare inequities

CME Information is available in the activity.


Webinar | Oncology | CME (AMA PRA Category 1 Credit) | 0.50 - 30 mins | Hematology | Internal Medicine | Family Medicine | Nurse | Nurse Practitioner | Online | Blood Management | Animation | Physician Assistant | AAPA | ANCC | Myelofibrosis | 

The France Foundation

A ACCME Accredited provider.

The France Foundation ©

Chandler Building, 84 Lyme Street, Old Lyme, CT USA